Henogen S.A. acquires 4C Biotech S.A.
Henogen, located at Charleroi in Belgium, has recently closed the acquisition of 4C Biotech, Seneffe, a Contract Manufacturing Organization dedicated to the development of mammalian cell culture processes for the production of biotherapeutics. This acquisition extends the existing services portfolio of Henogen « from gene to GMP clinical batch production « to the large scale production of monoclonal antibodies and recombinant proteins.
The new 60 people strong company will operate on two GMP sites, with more than 10 BL2/BL3 culture and purification suites equipped with the latest bioreactors up to 300L capacity .
· The site of Charleroi will be dedicated to the Bacteria, yeast, baculovirus and viral vectors productions. · The site of Seneffe will be dedicated to the large scale production of monoclonal antibodies and recombinant proteins thanks to its historical know-how regarding the perfused culture of mammalian cells .
Henogen now offers to the biopharmaceutical community a very complete services portfolio which starts from the molecular biology and the choice of the best expression system up to the sterile filling and the release of phase I/II clinical grade material.
Quite unique in Europe, such an integrated service targets a wide range of customers whether large pharmaceutical companies, innovative drug discovery biotech SME's or health related public institutions.
Other news from the department business & finance
These products might interest you

Flexcell Zelldehnungsbioreaktoren für zelluläre Biomechanik-Anwendungen by Dunn
Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 9000 research publications

Biostat STR by Sartorius
Biostat STR Generation 3 Bioreactors
Engineered for Ultimate Upstream Performance

Ambr® 250 HT Consumables by Sartorius
Efficient bioprocesses with single-use bioreactors
Minimise cleaning effort and maximise flexibility for cell and microbial cultures

Ambr® 250 Modular by Sartorius
Mini bioreactors for cell and gene therapies with high scalability
Maximise your process development with reliable single-use vessels

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous